UNSPSC 51294403: Aripiprazole

This classification denotes an antipsychotic agent with the molecular formula C23H27Cl2N3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 82VFR53I78, chemically known as 7-(4-(4-(2,3-dichlorophenyl)-1-piperazinyl)butyloxy)-3,4-dihydro-2(1h)-quinolinone but generally known as aripiprazole, which bears US NIH Compound Identifier 60795. European Medicines Agency schedules Aripiprazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05564MIG.

UNSPSC 51294403 Aripiprazole is a Commodity code that encompasses pharmaceutical procurement by state and local health agencies, though the recent opportunities tagged under it show substantial scope drift from the code's nominal single-drug classification. State and local buyers are procuring aripiprazole as part of broader pharmaceutical benefit programs, community health initiatives, and multi-drug cooperative purchasing contracts that include generic pharmaceuticals, over-the-counter products, and medications like naloxone that address public health priorities beyond psychiatry. The issuing bodies span state health and human services departments, county health departments, and statewide cooperative purchasing alliances coordinating across multiple participating jurisdictions. Work solicited includes annual supply contracts with quarterly or ongoing deliveries to health facilities, direct-to-manufacturer prescription fulfillment programs, and bulk pharmaceutical distribution through authorized wholesalers with fixed or negotiated net pricing models.

Recent activity clusters in Texas, Minnesota, and Florida. The Texas Health and Human Services Commission issued an RFI (Request for Information) on April 3, 2026, seeking vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements. The Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), posted an RFP on January 20, 2026, due March 26, 2026, for generic multi-source pharmaceuticals and OTC products to be distributed through authorized wholesalers effective July 1, 2026, with evaluation weighted 75 percent on price competitiveness and 25 percent on administrative compliance and EDI capability. Seminole County, Florida issued an IFB (Invitation for Bid) on June 30, 2026, due July 26, 2023, for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, though this opportunity's nominal coding under aripiprazole appears misaligned with the actual procurement scope.